Emerald Advisers’s Acceleron Pharma XLRN Stock Holding History

Emerald Advisers’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,712	Closed	-$340K	–	304
2021 Q2	$340K	Sell	2,712 -1,761	-39%	-$222K	0.01%	212
2021 Q1	$607K	Sell	4,473 -180	-4%	-$23.3K	0.02%	180
2020 Q4	$595K	Buy	4,653 +1,935	+71%	+$227K	0.02%	187
2020 Q3	$306K	Buy	+2,718	New	+$271K	0.01%	207

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Emerald Advisers's XLRN Position: Q3 2021 in Review

Emerald Advisers sold out of Acceleron Pharma (XLRN) in Q3 2021, closing a stake of 2,712 shares — an estimated $340K sold.

Emerald Advisers first reported a position in XLRN in Q3 2020 and held it in 4 quarters. The position peaked at $607K in Q1 2021. 330 funds tracked by Wall St. Rank hold XLRN as of Q3 2021.

Emerald Advisers reported no remaining Acceleron Pharma position as of Q3 2021 after selling out during the quarter.
Emerald Advisers sold 2,712 Acceleron Pharma shares in Q3 2021, an estimated $340K.
Emerald Advisers first reported a position in Acceleron Pharma in Q3 2020 and held it in 4 quarters.
Emerald Advisers's Acceleron Pharma position peaked at $607K in Q1 2021.
330 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2021.

Based on Emerald Advisers's 13F filing for Q3 2021, filed 28 Oct 2021.